Results 211 to 220 of about 216,461 (262)

Case 341

2010
openaire   +2 more sources

Bibliography 341

2016
openaire   +2 more sources

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Oncogene, 2004
Klaus Podar, Kenji Ishitsuka, Constantine Mitsiades   +2 more
exaly  

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

Oncogene, 2003
Wei-Xing Zong, Zong Wei-Xing, Thompson Craig B   +2 more
exaly  

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors

Oncogene, 2005
Kenji Ishitsuka, Hiroshi Yasui, Shaji Kumar   +2 more
exaly  

17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341–Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways

American Journal of Respiratory Cell and Molecular Biology, 2015
Kyoung-Hee Lee, An-Hee Jang, Chul-Gyu Yoo   +2 more
exaly  

Vorbemerkungen vor §§ 341–341 o

2013
openaire   +1 more source

THD-341

Drugs of the Future, 1978
J. Castañer, P. Blancafort
openaire   +1 more source

Detection of a novelHLA-C*07:341variant,HLA-C*07:341:02,in a Taiwanese hematopoietic stem cell donor

Hla, 2016
Kuo-Liang Yang, J H Hung
exaly  

Anmerkungen 341

2016
openaire   +1 more source